Effectively there are no competitors - that is why the FDA has granted orphan status for Dimerix' DMX-200 combo (propagermanium+irbesartan).. Current standard of care is irbesartan, which is off-license (generic is available). Irbesartan was originally developed to treat high blood pressure I believe.
Effectively there are no competitors - that is why the FDA has...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.020(5.26%) |
Mkt cap ! $200.5M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.3¢ | 35.0¢ | $1.228M | 3.287M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 54500 | 3 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |